Subscribe
Share
Share
Embed
Daily News from National Health Executive
And here’s today’s news from National Health Executive on Wednesday the 7th of August 2024.
The National Institute for Health and Care Excellence has approved the drug abaloparatide, which is marketed as Eladynos by Theramex, as an option for treating osteoporosis after the menopause, in a move that is expected to benefit more than 14,000 women. The treatment will be available for NHS use within the next three months and will be for those who are at a very high risk of fracture.
It will be as an alternative for people who have tried usual treatment options but either cannot tolerate them or have not responded to them. NICE describes abaloparatide as a “clinically and cost-effective” new option.
The government has announced that the NHS will be one of the beneficiaries of a series of artificial intelligence projects that are set to receive a share of £32m of funding. As part of the government’s mission to build an NHS which is fit for the future, pharmacies that deliver prescriptions across the country are set to benefit from this new financial support.
A project led by Nottingham-based Anteam will see them working alongside retailers and the NHS to improve the efficiency of their deliveries using AI algorithms. This technology will match the delivery needs of retailers and hospitals to existing delivery journeys, unlocking under-utilised capacity, cutting carbon emissions and delivering a better experience for patients.
And that’s the latest – Don’t forget to like and subscribe to make sure you receive every new bulletin & check out our website National Health Executive .com